Logo
image_janssen-support

Patient Management

Each patient should be up-titrated to the highest individually tolerated dose. Titration enables patients to reach their personalised dose of UPTRAVI®, which can range from 200 mcg twice daily to 1,600 mcg twice daily.[1] Prostacyclin-associated adverse reactions are an indirect sign of efficacious activation of the receptors and help determine each patient’s personalised dose of UPTRAVI®.[1][2]

Side effects during titration can be managed with over-the-counter remedies[2] and taking the first dose of a new titration step in the evening.[1] They often level off once the patient reaches their personalised maintenance dose.[2]

The goal for every patient is not to reach the maximum dose of 1,600 mcg, but to reach the right dose for that individual.

uptravi-patient-graphs_-03_v2_(1).png


It’s important to explain to patients that side effects are expected, and that the goal is to reach the maximally tolerated dose. If side effects are not tolerable, the dose is reduced by one step. This represents the patient’s personalised maintenance dose.

In the GRIPHON study, the majority of adverse reactions were mild to moderate and prostacyclin-associated adverse events (AEs) were less frequent after the maintenance dose was reached.[1][3]

uptravi-patient-graphs_-09

*Other common adverse reactions include: haemoglobin decrease, hyperthyroidism, hypotension, abdominal pain, decreased appetite, weight decrease, nasal congestion, pain, urticaria, erythema and a reduction in thyroid-stimulating hormone. Rare adverse reactions: sinus tachycardia and increased heart rate.[1]

For complete information about the safety and tolerability of UPTRAVI®, please consult the local Summary of Product Characteristics.

Learn More About UPTRAVI®

Studies

Details of the GRIPHON study, where the safety and efficacy of UPTRAVI® were investigated in a Phase 3 study to assess the long-term benefits for pulmonary arterial hypertension (PAH) patients.

Guidelines

Details from the 2015 ESC/ERS guidelines to help you achieve and/or maintain a low-risk status for your patients with PAH.

References

Kingman M et al. Pulmonary Circ 2017; 7:598–608.
Sitbon O et al. N Engl J Med 2015; 373:2522–253.
EM- 50402